NDC 54868-0072

NDC 54868-0072

NDC 54868-0072 is a in the category. It is labeled and distributed by .

Proprietary NameNDC 54868-0072
Marketing Category/

Packaging

NDC SPL Data Element Entries

NDC 54868-0072-1 [54868007201]

ACETAMINOPHEN AND CODEINE PHOSPHATE TABLET
Marketing CategoryANDA
Application NumberANDA040419
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2003-09-25
Inactivation Date2019-09-24

NDC 54868-0072-7 [54868007207]

ACETAMINOPHEN AND CODEINE PHOSPHATE TABLET
Marketing CategoryANDA
Application NumberANDA040419
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2003-09-25
Inactivation Date2019-09-24

NDC 54868-0072-9 [54868007209]

ACETAMINOPHEN AND CODEINE PHOSPHATE TABLET
Marketing CategoryANDA
Application NumberANDA040419
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2003-09-25
Inactivation Date2019-09-24

NDC 54868-0072-2 [54868007202]

ACETAMINOPHEN AND CODEINE PHOSPHATE TABLET
Marketing CategoryANDA
Application NumberANDA040419
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2003-09-25
Inactivation Date2019-09-24

NDC 54868-0072-3 [54868007203]

ACETAMINOPHEN AND CODEINE PHOSPHATE TABLET
Marketing CategoryANDA
Application NumberANDA040419
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2003-09-25
Inactivation Date2019-09-24

NDC 54868-0072-8 [54868007208]

ACETAMINOPHEN AND CODEINE PHOSPHATE TABLET
Marketing CategoryANDA
Application NumberANDA040419
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2003-09-25
Inactivation Date2019-09-24

NDC 54868-0072-4 [54868007204]

ACETAMINOPHEN AND CODEINE PHOSPHATE TABLET
Marketing CategoryANDA
Application NumberANDA040419
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2003-09-25
Inactivation Date2019-09-24

NDC 54868-0072-5 [54868007205]

ACETAMINOPHEN AND CODEINE PHOSPHATE TABLET
Marketing CategoryANDA
Application NumberANDA040419
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2003-09-25
Inactivation Date2019-09-24

Drug Details


© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.